By Odelya Gertel Kraybill Ph.D.: For More Info, Go Here…
A new study* published in the Journal of Neurology Neurosurgery and Psychiatry asserts the efficacy of anti-inflammatories in treating major depression. This adds to the mounting evidence that there is a connection between emotional functioning and inflammation.
An increasing number of studies have shown that depression and/or bipolar disorder are accompanied by immune system dysregulation, inflammation, and high levels of cytokines. Researchers have found that inflammation triggers depression, almost like an allergic reaction.
In a meta-analysis of 30 randomized control trials (RCT) with 1610 participants, the authors examined the efficacy and safety of anti-inflammatory agents as either standalone or adjunct treatment of individuals with major depression. Anti-inflammatory treatments were defined as NSAIDs, omega-3 fatty acids (omega-3 FA), cytokine inhibitors, statins, corticosteroids, minocycline, pioglitazone, modafinil and N-acetylcysteine (NAC).
While the authors reported several methodological limitations, their systematic meta-analysis suggested that anti-inflammatory agents can safely and effectively reduce symptoms of major depression. A sub-analysis found that anti-inflammatories as adjunctive treatment with antidepressants with NSAIDs, omega-3 FAs, statins, and minocycline showed significant antidepressant effects for major depression.
